Today, Chiesi Global Rare Diseases announced that it has acquired Unikeris Limited. In the primary immunodeficiency world, Unikeris Limited is a global marketer for Revcovi for the treatment of ADA-SCID. ADA-SCID is a type of PI that occurs in approximately one in 200,000 to 1,000,000 newborns worldwide.
Chiesi Group Acquires Unikeris Limited and Adds Revcovi® (elapegademase-lvlr) Injection to Product Portfolio
- The addition of approved therapy for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) expands Chiesi commitment to addressing significant areas of unmet need in the treatment of rare diseases
- Under terms of the agreement, Chiesi Group has acquired all rights to Revcovi, which will continue to be available to patients through Chiesi Global Rare Diseases, a business unit of Chiesi Group
To read the full press release, please visit: https://www.chiesiglobalrarediseases.com/